In a search of small molecules active against apoptosis-resistant cancer cells, a skeletal rearrangement of alkaloid haemanthamine was utilized to generate a series of compounds possessing the alkaloid montanine ring system. The synthesized compounds were found to inhibit proliferation of cancer cells resistant to apoptosis at micromolar concentrations. Selected compounds were also active against patient-derived glioblastoma cells expressing stem-cell markers. This is the first report describing the preparation of synthetic analogues of the montanine-type alkaloids with antiproliferative activity. The compounds prepared in the current investigation appear to be a useful starting point for the development of agents to fight cancers with apoptosis resistance, and thus, associated with poor prognoses.
Cancers with intrinsic resistance to apoptosis are characterized by the lack of responsiveness to current chemotherapeutic agents that generally work by the induction of apoptosis in cancer cells. These cancers include tumors of the lung, melanoma and glioblastoma and they represent a major challenge in the clinic. 1 For example, patients afflicted by glioblastoma multiforme, 2,3 have a median survival expectancy of less than 14 months when treated with the best available protocol that involves surgery, radiation and chemotherapy with temozolomide. 4 Further, the main cause of death of cancer patients are tumor metastases. Metastatic cells are resistant to anoikis, a type of apoptotic cell death triggered by the loss of contact with extracellular matrix or neighboring cells. 5 Resistance to anoikis, and thus apoptosis, renders metastatic cells unresponsive to the large majority of proapoptotic agents as well. 3, 6 In addition, it is believed that a population of cancer cells, referred to as cancer stem cells, is particularly unresponsive to pro-apoptotic chemotherapy. Glioblastoma cells exhibiting stem cell markers (GSCs) can be grown in culture as neurospheres. They possess the ability to self-renew, differentiate into multiple neural lineages and faithfully recapitulate human glioblastoma on both histological and genetic levels when injected into the brains of mice. [7] [8] [9] Therefore, a search for novel anticancer agents that can overcome cancer cell resistance, including resistance to apoptosis, is an important pursuit.
In this connection, natural products represent a valuable source of not only cytotoxic compounds, but also those capable of overcoming the intrinsic resistance of cancer cells to apoptosis. [10] [11] [12] [13] Our recent studies have focused on isocarbostyrils and alkaloids belonging to the Amaryllidaceae plant family. The medicinal value of the Amaryllidaceae plants was already recognized in the fourth century BC, when Hippocrates of Cos used oil from the daffodil Narciclasus poeticus L. for the treatment of cancer. 14 In more recent times, over 100 structurally diverse alkaloids, possessing a wide spectrum of biological activities have been isolated from the Amaryllidaceae species. 15 Narciclasine and lycorine ( Figure 1 ) have been actively investigated for their potent anti-tumor effects, both in vitro and in vivo, in various pre-clinical models of human cancers by us [16] [17] [18] [19] [20] [21] and others. [22] [23] [24] [25] Our interest in these natural products primarily stems from their ability to overcome apoptosis resistance and display promising activity in orthotopic mouse models of glioblastoma and metastatic melanoma. 16, 19, 21 Although, not evaluated in vivo, crinine-type alkaloids, such as haemanthamine ( Figure 1 ) 17 and bulbispermine, 26 also show promising activity against apoptosis-resistant cancer cells. To investigate whether promising antiproliferative properties are also associated with other representative Amaryllidaceae alkaloid groups, we noted that montanine ( Figure   1 ) was shown to be cytotoxic to human cancer cells. 27 The montanine group of alkaloids is characterized by a 5,11-methanomorphanthridine ring system and some examples of the montanine-type alkaloids are shown in Figure 1 . The work reported in the current manuscript describes the first systematic attempt to assess the anticancer potential of compounds based on the montanine-type alkaloid structural system. Synthetic derivatization of the montanine-type alkaloids to generate a library of analogues is challenging because their stable and practical supply from the plant sources has not been established to our knowledge. In contrast, we and others have developed practical multigram isolation procedures for narciclasine, lycorine and haemanthamine. 28 We thus drew our attention to an old report of a semisynthetic transformation of haemanthamine-type skeleton to the montanine-type scaffold ( Figure 2 ). 29 This elegant work, which was reproduced in a later study, 30 described the intramolecular nucleophilic attack of the electron rich aromatic moiety on the activated C11-hydroxyl (A in Figure 2 ) to form the C10a-C11 bond presumably leading to the arenium ion B. The C10a-C10b bond then breaks upon the S N 2' attack of a nucleophile at C2 with the translocation of the C1-C2 alkene to the C1-C10b position resulting in the montanine-type skeleton C (Figure 2 ).
The reaction can be conducted without the addition of an external nucleophile for 48 h at rt, in which case it will result in chlorine-containing derivative 1, where the chloride liberated upon mesylation serves as the nucleophile (Figure 3 ). 29 Alternatively, the reaction can be run at 0 °C for 8 hours with the subsequent addition of a nucleophilic species. In this case a wide variety of C2-substituted montanine-type synthetic derivatives can be prepared. Thus, the addition of water results in 2. 29 The addition of methoxide, prepared by the reaction of MeOH with NaH leads to another montanine-type alkaloid manthine, isolated by Wildman from South African plant genus Haemanthus. 29, 31 Depending on the species the yield varied from 1 to 44 mg per kg of wet bulbs, clearly insufficient for its supply for biological studies. 31 This alkaloid was also obtained by a total synthesis by Sha and coworkers, which involved a 24-step procedure from commercially available quinic acid. 32 The one step synthesis of manthine from haemanthamine, readily available in multigram quantities, is thus significant.
We found that other nucleophiles that can be utilized in this transformation are ethanol, allylic and propargylic alcohols, leading to compounds 3, 4 and 5. In addition, a primary amine, indole and pyrrole can be added to the C2-position quite readily following their deprotonation with NaH, resulting in 6, 7 and 8 (Figure 3 ). In the case of indole, only C3alkylation was observed, although both N1-and C3-alkylations are possible.
Because chloride 1 could be readily prepared on the preparative scale, it was utilized in further transformations, involving N-oxidation, N-propargylation, and single or double iodination of the aromatic ring, resulting in derivatives 9, 10, 11 and 12, respectively ( Figure  4A ). In addition, 2 can be converted to bromide 13 ( Figure 3B ). Finally, we found that the transformation of the crinine to montanine skeleton can be also achieved using a related alkaloid, haemanthidine ( Figure 4C ). Here, the C6-mesylated product 14 was isolated in a reasonable yield. The stability of the mesylate is accounted for by the bridgehead nature of the tertiary nitrogen and thus its inability to stabilize the adjacent positive charge that would develop in the transition state of the hydrolysis reaction. 33, 34 The synthesized compounds were evaluated for in vitro antiproliferative properties using the MTT colorimetric assay against a panel of six cancer cell lines. 35 This included cells resistant to a number pro-apoptotic stimuli, such as human A549 non-small cell lung cancer (NSCLC), human glioblastoma U373, and human SKMEL-28 melanoma, as well as tumor models, which are largely susceptible to apoptosis-inducing stimuli, such as human Hs683 anaplastic oligodendroglioma, human MCF-7 breast adenocarcinoma and mouse B16F10 melanoma ( Table 1) . Analysis of these data reveals that the active derivatives displayed comparable potencies in both cell types, irrespective to cell sensitivities to apoptosis induction and suggesting that they are capable of overcoming apoptosis resistance (Table 1) .
Despite the large variations in cancer cell line sensitivities, the data indicate that a small C2substituent is preferred as observed in chloride 1, alcohol 2 and bromide 13. Activity of chloride 1 and bromide 13, in which the halogen atom has the inverted configuration, appears to indicate that the α-C2 configuration is not critical. The variations in cell line sensitivities to both chloride 1 and bromide 13 suggest that they are not indiscriminate alkylating agents, but have distinct intracellular targets. Of the C2-ethers, alkaloid manthine, containing the small C2-methoxy group, stands out by affording single digit GI 50 values across the entire panel, including the glioblastoma U373 cells for which 1 and 2 are less effective. The replacement of the C2-OMe by the C2-OEt leads to the loss of activity as observed in 3. The activity is regained by the introduction of a multiple bond as in 4 and 5.
Of the compounds possessing larger C2-substuents, the indole-containing compound 7 exhibited single-digit GI 50 values against several cell lines. Further, the quaternization of the nitrogen (9 and 10) gives inactive compounds as well. It is likely that in this case the charged derivatives cannot cross the cell membrane. Finally, the substitution pattern on the aromatic ring appears to be critical as well, since the derivatization of the C7 and C10 positions (11 and 12) leads to inactive compounds. Table 1 were evaluated against a patient-derived GSC22 cell line that was authenticated for stem-like properties by validating self-renewal (sphere formation), expression of stem-cell markers (CD133, nestin), multilineage differentiation, and high efficiency for orthotopic in vivo tumor initiation in immunodeficient NOD SCID mice, as reported previously. 36, 37 Figure 5 shows that manthine, compound 7 and haemanthamine significantly reduced proliferation at concentrations as low as 1 μM. All tested compounds inhibited proliferation by 80-95% at concentrations of 10 and 30 μM.
Selected compounds, showing the highest potency in
In conclusion, utilizing a previously described transformation of the crinine to montaninetype skeletons, we prepared the first series of synthetic analogues of the montanine alkaloids differing by the substituents at C2, N5, C6, C7 and C10 positions. It was found that the reaction readily proceeded not only with oxygen or halogen-based nucleophiles, but also with primary amines and nucleophilic heterocycles. The synthesized compounds were found to inhibit proliferation of cancer cells resistant to apoptosis at micromolar concentrations, with alkaloid manthine, C2-OH and C2-indole-substituted compounds appearing to be most potent. Selected compounds also were active against patient-derived glioblastoma cells expressing stem-cell markers. These preliminary results indicate that compounds based on the montanine skeleton should be investigated as potential anticancer agents active against drug-resistant cancer cells, including cancer stem cells. Brdu incorporation in GSC22 cells following 72 h drug treatment. 38 Data are means ± SEM, n=3; *P < 0.05 versus vehicle control. Table 1 In vitro growth inhibitory effects of compounds 1-4 and alkaloid manthine 
